Published Date: 17 Mar 2023
UK: A recent study published in BMJ Medicine found that more caffeine in the blood can reduce the risk of type 2 diabetes and obesity. more...
Read Full NewsAn investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.
A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.
The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.
Both drugs increase overall and progression-free survival.
1.
Global inequalities found in cancer research funding
2.
Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.
3.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
4.
Active Surveillance Lawsuits; More Eligibility for Studies; Biosimilars Make News.
5.
Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer
1.
Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics
2.
Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More
3.
Hypercoagulable State: Factors that Contribute to Blood Clots
4.
Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology
5.
What Is Carboxyhemoglobin And How Can It Affect Your Health?
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part III
2.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
3.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation